Targeted Oncology™ announces recipients of its Oncology Icons award program
15 nov. 2023 14h10 HE
|
Targeted Oncology™
CRANBURY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of...
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
03 août 2023 16h05 HE
|
Immuneering Corporation
- Positive initial pharmacokinetic, pharmacodynamic and safety data presented at American Association for Cancer Research (AACR) annual meeting, with IMM-1-104 demonstrating Cmax, half-life, and...
Targeted Oncology™ announces recipients of its Q2 Oncology Icons award program
18 juil. 2023 10h44 HE
|
Targeted Oncology™
CRANBURY, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Targeted Oncology, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of...
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
12 avr. 2023 16h05 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
05 avr. 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
14 mars 2023 16h30 HE
|
Immuneering Corporation
Demonstrates ability to identify patient populations that may benefit from IMM-1-104 treatment Biomarker discovery and clinical translation supports patient selection in ongoing Phase 1/2a clinical...
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
05 mars 2023 18h30 HE
|
Immuneering Corporation
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid...
Immuneering Announces Participation in March Investor Conferences
28 févr. 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
27 févr. 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
SEngine Precision Medicine Announces New Non-Small Cell Lung Cancer Study at Johns Hopkins University
27 sept. 2022 14h58 HE
|
SEngine Precision Medicine, Inc.
SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D...